PharmaNutra - Public Comps and Valuation Multiples

PharmaNutra Overview

About PharmaNutra

PharmaNutra SpA is a pharmaceutical company. The company is engaged in the research, design, development, and marketing of nutraceutical supplements and medical devices. The products of the company include SiderAL Folic, UltraMag, Cetilar, and others. The company operates in Europe, the Middle East, South America, the Far East, Asia and others.

Founded

2003

HQ

Employees

118

Website

pharmanutra.it

Sectors

Nutraceuticals & Cosmeceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $152M

LTM EBITDA $38.8M

EV

$632M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

PharmaNutra Financials

As of November 2025, PharmaNutra reported last 12-month revenue of $152M and EBITDA of $38.8M.

In the same period, PharmaNutra achieved $22.2M in LTM net income.

See PharmaNutra valuation multiples based on analyst estimates

PharmaNutra P&L

In the most recent fiscal year, PharmaNutra reported revenue of $136M and EBITDA of $37.4M.

PharmaNutra expects next 12-month revenue of XXX and NTM EBITDA of XXX

See PharmaNutra valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$152M	XXX	$136M	XXX	XXX	XXX
Gross Profit	n/a	XXX	$96.3M	XXX	XXX	XXX
Gross Margin	n/a	XXX	71%	XXX	XXX	XXX
EBITDA	$38.8M	XXX	$37.4M	XXX	XXX	XXX
EBITDA Margin	26%	XXX	28%	XXX	XXX	XXX
EBIT	$33.9M	XXX	$32.4M	XXX	XXX	XXX
EBIT Margin	22%	XXX	24%	XXX	XXX	XXX
Net Profit	$22.2M	XXX	$19.3M	XXX	XXX	XXX
Net Margin	15%	XXX	14%	XXX	XXX	XXX
Net Debt	XXX	XXX	$8.1M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for PharmaNutra including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $152M. EBITDA for the last twelve months was $38.8M. In the most recent fiscal year, PharmaNutra achieved $136M in revenue and $37.4M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$152M	Analyst estimates available to subscribers	$136M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	$96.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	70.9% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$38.8M	Analyst estimates available to subscribers	$37.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	25.6% EBITDA margin	Analyst estimates available to subscribers	27.5% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$33.9M	Analyst estimates available to subscribers	$32.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	22.3% EBIT margin	Analyst estimates available to subscribers	23.8% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$22.2M	Analyst estimates available to subscribers	$19.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	14.6% net profit margin	Analyst estimates available to subscribers	14.2% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$8.1M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for PharmaNutra

This financial data table provides comprehensive performance metrics for PharmaNutra, a company based in Italy. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

PharmaNutra generated $152M in revenue over the last twelve months.
The company achieved $38.8M in EBITDA over the last twelve months.
Net income over the last twelve months reached $22.2M.

Fiscal Year Performance

In the most recent fiscal year, PharmaNutra reported $136M in total revenue.
Fiscal year EBITDA was $37.4M.
The company maintained a gross profit margin of 70.9% in the most recent fiscal year.
EBITDA margin for the fiscal year was 27.5%.
Net profit margin reached 14.2% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for PharmaNutra. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

PharmaNutra Stock Performance

PharmaNutra has current market cap of EUR 545M (or $633M), and EV of EUR 544M (or $632M).

Market Cap Evolution

PharmaNutra Stock Data

As of December 4, 2025, PharmaNutra's stock price is EUR 57 (or $66).

See PharmaNutra trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$632M	$633M	XXX	XXX	XXX	XXX	$2.30

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

PharmaNutra Valuation Multiples

PharmaNutra's trades at 4.7x EV/Revenue multiple, and 16.9x EV/EBITDA.

See valuation multiples for PharmaNutra and 15K+ public comps

PharmaNutra Financial Valuation Multiples

As of December 4, 2025, PharmaNutra has market cap of $633M and EV of $632M.

Equity research analysts estimate PharmaNutra's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

PharmaNutra has a P/E ratio of 28.5x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$633M	XXX	$633M	XXX	XXX	XXX
EV (current)	$632M	XXX	$632M	XXX	XXX	XXX
EV/Revenue	4.2x	XXX	4.7x	XXX	XXX	XXX
EV/EBITDA	16.3x	XXX	16.9x	XXX	XXX	XXX
EV/EBIT	18.7x	XXX	19.5x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	28.5x	XXX	32.8x	XXX	XXX	XXX
EV/FCF	39.5x	XXX	33.5x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get PharmaNutra Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

PharmaNutra Margins & Growth Rates

PharmaNutra's last 12 month revenue growth is 14%

PharmaNutra's revenue per employee in the last FY averaged $1.2M, while opex per employee averaged $0.5M for the same period.

PharmaNutra's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

PharmaNutra's rule of X is 60% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for PharmaNutra and other 15K+ public comps

PharmaNutra Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	14%	XXX	13%	XXX	XXX	XXX
EBITDA Margin	26%	XXX	28%	XXX	XXX	XXX
EBITDA Growth	17%	XXX	13%	XXX	XXX	XXX
Rule of 40	40%	XXX	41%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	60%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$1.2M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.5M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	26%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	1%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	47%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial